XLifeSc Announces that Axis Receives FDA Clearance for TCR-T Cell Therapy IND to Initiate Clinical Trials in the USA

FDA Acceptance for Filing of U.S. NDA for Oral Paclitaxel and Encequidar in Metastatic Breast Cancer with Priority Review

Guangzhou Xiangxue Pharmaceutical Expands its Strategic Partnership with Athenex Inc. through a Licensing Agreement for the Product Candidates Oral Paclitaxel, Oral Irinotecan, and Tirbanibulin Ointment, in China

XLifes once again named “top 50 biotechnology enterprises” of GAB

Initiation of Phase I Clinical Study in China of KX2-361 Oral by XPH